JPH0581600B1 - - Google Patents

Info

Publication number
JPH0581600B1
JPH0581600B1 JP1500565A JP50056589A JPH0581600B1 JP H0581600 B1 JPH0581600 B1 JP H0581600B1 JP 1500565 A JP1500565 A JP 1500565A JP 50056589 A JP50056589 A JP 50056589A JP H0581600 B1 JPH0581600 B1 JP H0581600B1
Authority
JP
Japan
Prior art keywords
hcv
cdna
sequence
clone
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP1500565A
Other languages
English (en)
Japanese (ja)
Other versions
JPH02500880A (ja
Inventor
Michael Houghton
Qui-Lim Choo
George Kuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27557988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0581600(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of JPH02500880A publication Critical patent/JPH02500880A/ja
Publication of JPH0581600B1 publication Critical patent/JPH0581600B1/ja
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
JP89500565A 1987-11-18 1988-11-18 Ｎａｎｂｖの診断用薬およびワクチン Expired - Lifetime JPH02500880A (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US12271487A 1987-11-18 1987-11-18
US122,714 1987-11-18
US13988687A 1987-12-30 1987-12-30
US16107288A 1988-02-26 1988-02-26
US161072 1988-02-26
US19126388A 1988-05-06 1988-05-06
US191263 1988-05-06
US26358488A 1988-10-26 1988-10-26
US27145088A 1988-11-14 1988-11-14
US263,584 1988-11-14
US139,886 1988-11-14
US271,450 1988-11-14

Related Child Applications (5)

Application Number Title Priority Date Filing Date
JP4361784A Division JP2809956B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬
JP4361787A Division JP2662351B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬およびワクチン
JP4361786A Division JP2532805B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬およびワクチン
JP4361785A Division JP2662350B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬
JP5178446A Division JP2662358B2 (ja) 1987-11-18 1993-06-11 Ｎａｎｂｖの診断用薬

Publications (2)

Publication Number Publication Date
JPH02500880A JPH02500880A (ja) 1990-03-29
JPH0581600B1 true JPH0581600B1 (2) 1993-11-15

Family

ID=27557988

Family Applications (16)

Application Number Title Priority Date Filing Date
JP89500565A Expired - Lifetime JPH02500880A (ja) 1987-11-18 1988-11-18 Ｎａｎｂｖの診断用薬およびワクチン
JP4361786A Expired - Lifetime JP2532805B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬およびワクチン
JP4361785A Expired - Lifetime JP2662350B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬
JP4361787A Expired - Lifetime JP2662351B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬およびワクチン
JP4361784A Expired - Lifetime JP2809956B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬
JP5178446A Expired - Lifetime JP2662358B2 (ja) 1987-11-18 1993-06-11 Ｎａｎｂｖの診断用薬
JP8239921A Expired - Lifetime JP2810022B2 (ja) 1987-11-18 1996-08-21 Ｎａｎｂｖの診断用薬
JP24145196A Expired - Lifetime JP3171793B2 (ja) 1987-11-18 1996-08-22 Ｎａｎｂｖの診断用薬
JP9099651A Expired - Lifetime JP2810032B2 (ja) 1987-11-18 1997-04-01 Ｎａｎｂｖの診断用薬
JP10111631A Pending JPH10290696A (ja) 1987-11-18 1998-04-06 Ｎａｎｂｖの診断用薬およびワクチン
JP10111632A Pending JPH10290697A (ja) 1987-11-18 1998-04-06 Ｎａｎｂｖの培養法
JP11157193A Pending JP2000023683A (ja) 1987-11-18 1999-06-03 Ｎａｎｂｖの診断用薬
JP2005325486A Withdrawn JP2006117681A (ja) 1987-11-18 2005-11-09 Ｎａｎｂｖの診断用薬およびワクチン
JP2005325483A Withdrawn JP2006104207A (ja) 1987-11-18 2005-11-09 Ｎａｎｂｖの診断用薬
JP2007095590A Pending JP2007197456A (ja) 1987-11-18 2007-03-30 Ｎａｎｂｖの診断用薬
JP2007179093A Pending JP2008007508A (ja) 1987-11-18 2007-07-06 Ｎａｎｂｖの診断用薬およびワクチン

Family Applications After (15)

Application Number Title Priority Date Filing Date
JP4361786A Expired - Lifetime JP2532805B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬およびワクチン
JP4361785A Expired - Lifetime JP2662350B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬
JP4361787A Expired - Lifetime JP2662351B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬およびワクチン
JP4361784A Expired - Lifetime JP2809956B2 (ja) 1987-11-18 1992-12-16 Ｎａｎｂｖの診断用薬
JP5178446A Expired - Lifetime JP2662358B2 (ja) 1987-11-18 1993-06-11 Ｎａｎｂｖの診断用薬
JP8239921A Expired - Lifetime JP2810022B2 (ja) 1987-11-18 1996-08-21 Ｎａｎｂｖの診断用薬
JP24145196A Expired - Lifetime JP3171793B2 (ja) 1987-11-18 1996-08-22 Ｎａｎｂｖの診断用薬
JP9099651A Expired - Lifetime JP2810032B2 (ja) 1987-11-18 1997-04-01 Ｎａｎｂｖの診断用薬
JP10111631A Pending JPH10290696A (ja) 1987-11-18 1998-04-06 Ｎａｎｂｖの診断用薬およびワクチン
JP10111632A Pending JPH10290697A (ja) 1987-11-18 1998-04-06 Ｎａｎｂｖの培養法
JP11157193A Pending JP2000023683A (ja) 1987-11-18 1999-06-03 Ｎａｎｂｖの診断用薬
JP2005325486A Withdrawn JP2006117681A (ja) 1987-11-18 2005-11-09 Ｎａｎｂｖの診断用薬およびワクチン
JP2005325483A Withdrawn JP2006104207A (ja) 1987-11-18 2005-11-09 Ｎａｎｂｖの診断用薬
JP2007095590A Pending JP2007197456A (ja) 1987-11-18 2007-03-30 Ｎａｎｂｖの診断用薬
JP2007179093A Pending JP2008007508A (ja) 1987-11-18 2007-07-06 Ｎａｎｂｖの診断用薬およびワクチン

Country Status (18)

Country Link
EP (1) EP0318216B2 (2)
JP (16) JPH02500880A (2)
KR (2) KR0138776B1 (2)
CN (5) CN1074422C (2)
BR (1) BR8807310A (2)
CA (1) CA1341629C (2)
DE (2) DE3886363T3 (2)
ES (1) ES2012739T5 (2)
FI (3) FI105652B (2)
GR (1) GR900300069T1 (2)
HK (1) HK38293A (2)
HU (3) HU216017B (2)
IE (1) IE62868B1 (2)
LV (1) LV10726B (2)
NO (1) NO304990B1 (2)
NZ (1) NZ227011A (2)
UA (1) UA42668C2 (2)
WO (1) WO1989004669A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004506018A (ja) * 2000-08-17 2004-02-26 トリペップ　アクチ　ボラゲット リバビリンを含むワクチンおよびその使用方法

Families Citing this family (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
AU650038B2 (en) * 1988-03-11 1994-06-09 Abbott Laboratories CKS method of protein synthesis
JP2696116B2 (ja) * 1988-09-30 1998-01-14 財団法人阪大微生物病研究会 非ａ非ｂ肝炎患者の血清と抗原抗体反応するペプチド、及び該ペプチドをコードするｄｎａ
US5191064A (en) * 1988-09-30 1993-03-02 The Research Foundation For Microbial Diseases (Osaka University) Non-a, non-b hepatitis virus antigen peptide
JPH02167081A (ja) * 1988-12-21 1990-06-27 Tetsuo Nakamura 非Ａ非Ｂ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡおよびウイルス抗原蛋白質
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
ATE211772T1 (de) * 1989-05-18 2002-01-15 Chiron Corp Nanbv-diagnostika: polynukleotide, geeignet für reihenuntersuchungen auf hepatitis c-virus
JPH0330676A (ja) * 1989-06-28 1991-02-08 Sanwa Kagaku Kenkyusho Co Ltd 非ａ非ｂ型肝炎ウイルスのｄｎａ、そのクローン及びこれらの調製法
EP0416725A3 (en) * 1989-07-14 1991-03-20 Chugai Seiyaku Kabushiki Kaisha Blood-borne non-a, non-b hepatitis specific protein, dna encoding it, and process for its production
ATE161041T1 (de) * 1989-08-25 1997-12-15 Chiron Corp Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
WO1991004262A1 (en) * 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
FR2654113A1 (fr) * 1989-11-09 1991-05-10 Pasteur Institut Procede de diagnostic de virus appartenant a la famille des flaviviridae.
GR1001261B (el) * 1989-12-18 1993-06-30 Wellcome Found Ιϊκός παράγων.
US7166287B1 (en) 1989-12-18 2007-01-23 Glaxo Wellcome Inc. Viral agent
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
CA2032907C (en) * 1989-12-22 2002-05-14 Richard R. Lesniewski Hepatitis c assay
EP0435229A1 (en) * 1989-12-27 1991-07-03 Sanwa Kagaku Kenkyusho Co., Ltd. DNA of non-A, non-B hepatitis virus gene, its clone and use thereof
CA2036022A1 (en) * 1990-02-09 1991-08-10 Tetsuo Nakamura Non-a, non-b hepatitis related nucleic acids, antigens, antibodies and their detection reagents
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
US5639594A (en) * 1990-02-16 1997-06-17 United Biomedical, Inc. Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
EP0445801A3 (en) * 1990-03-08 1992-07-01 Kuraray Co., Ltd. Peptide and its use
EP0447984A1 (en) * 1990-03-20 1991-09-25 Abbott Laboratories Hyperimmune globulin against hepatitis C virus and method for making same
WO1991014779A1 (fr) * 1990-03-28 1991-10-03 Mitsui Toatsu Chemicals, Incorporated Diagnostic du virus de l'hepatite
JPH0436185A (ja) * 1990-03-28 1992-02-06 Kyowa Hakko Kogyo Co Ltd 融合抗原ポリペプチド
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
HU217025B (hu) * 1990-04-04 1999-11-29 Chiron Corp. Hepatitis C vírus-(HCV) antigénkészítmények az anti-HCV-antitestek kimutatására immunoassay-kben
US5712087A (en) * 1990-04-04 1998-01-27 Chiron Corporation Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens
DE69133402T2 (de) * 1990-04-04 2004-11-11 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Protease von hepatitis-c-virus
DE69132332T2 (de) * 1990-04-06 2000-11-30 Genelabs Technologies, Inc. Hepatitis c-virus-epitope
JP3050395B2 (ja) * 1990-06-12 2000-06-12 国立感染症研究所長 Ｃ型肝炎ウイルス抗原ポリペプチド、その産生方法および抗体の検出方法
CA2044296A1 (en) * 1990-06-12 1991-12-13 Hiroaki Okamoto Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus
AU652941B2 (en) * 1990-06-25 1994-09-15 Research Foundation For Microbial Diseases Of Osaka University, The Non-A, Non-B hepatitis virus particles
US5747339A (en) * 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
EP0933426A1 (en) * 1990-06-25 1999-08-04 The Research Foundation for Microbial Diseases of Osaka University Non-a, non-b hepatitis virus genomic cdna fragments and antigen polypeptides
FI923020A0 (fi) * 1990-06-30 1992-06-29 Akzo Nv Inte a inte b-sekvenser.
KR0181517B1 (ko) * 1990-07-09 1999-04-01 나까하라 노부유끼 비-에이 비-비형 간염-특이 항원 및 간염 진단에서 그의 용도
DE69125066T2 (de) * 1990-07-11 1997-09-25 Shionogi Seiyaku K K Trading U cDNS-Sequenz und Detektion des Hepatitis C-Virus
WO1992001714A1 (fr) * 1990-07-24 1992-02-06 Yamanouchi Pharmaceutical Co., Ltd. Antigene du virus de l'hepatite non a, non b
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
WO1992002642A1 (en) * 1990-08-10 1992-02-20 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
US6172189B1 (en) * 1990-08-24 2001-01-09 Abbott Laboratories Hepatitis C assay utilizing recombinant antigens
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
WO1992003458A1 (en) * 1990-08-25 1992-03-05 New York Blood Center Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines
US7863008B2 (en) 1990-08-25 2011-01-04 Bioprocess Pty Ltd. Method for detecting NANBV associated seroconversion
KR930702506A (ko) * 1990-10-12 1993-09-09 찰스 엠. 브록 C형 간염 바이러스 항체
JP3549201B2 (ja) * 1990-10-24 2004-08-04 中外製薬株式会社 非ａ非ｂ型肝炎特異的遺伝子の検出方法及び検出用試薬組成物
ATE318309T1 (de) * 1990-11-03 2006-03-15 Dade Behring Marburg Gmbh Hcv-spezifische peptide, mittel dazu und ihre verwendung
DE4034982C2 (de) * 1990-11-03 1999-12-23 Dade Behring Marburg Gmbh Synthetische Polypeptide zur Bestimmung von HCV-Antikörpern und HCV-Antigenen, Mittel dazu und ihre Verwendung in diesen Nachweis-Verfahren
DE4121431A1 (de) * 1991-06-28 1993-01-07 Behringwerke Ag Synthetische core-peptide zur bestimmung von hcv-antikoerpern und hcv-antigenen, mittel dazu und ihre verwendung in diesen nachweis-verfahren
DE4120281C2 (de) * 1991-06-19 1999-11-25 Dade Behring Marburg Gmbh Immunchemisches Verfahren zum gleichzeitigen Nachweis von mehreren verschiedenen Antikörperspezifitäten, Peptidmischungen und Test dazu
DE4112743C2 (de) * 1991-04-19 2000-01-13 Dade Behring Marburg Gmbh Synthetische Core-Peptide zur Bestimmung von HCV-Antikörpern und HCV-Antigenen, Mittel dazu und ihre Verwendung in diesen Nachweis-Verfahren
US5753430A (en) * 1990-11-07 1998-05-19 Abbott Laboratories Monoclonal antibodies to hepatitis C virus and method for using same
JP3242402B2 (ja) * 1990-11-07 2001-12-25 アボット・ラボラトリーズ Ｃ型肝炎ウイルスに対するモノクローナル抗体およびその使用法
CA2055149A1 (en) * 1990-11-08 1992-05-09 Hiroaki Okamoto Non-a, non-b hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides
SK286106B6 (sk) * 1990-11-08 2008-03-05 Novartis Vaccines & Diagnostics, Inc. Spôsob vykonávania imunodiagnostickej skúšky na detekciu protilátky proti vírusu hepatitídy C
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
EP0516859A1 (en) * 1990-11-29 1992-12-09 Toray Industries, Inc. Non-a non-b hepatitis virus antigen protein
DK0488812T3 (da) * 1990-11-30 1999-12-13 Japan Immuno Inc Non-A, non-B hepatitis-relaterede nucleinsyrer, antigener og antistoffer samt reagenser til deres påvisning
US6007982A (en) * 1990-12-14 1999-12-28 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus
US5910404A (en) 1990-12-14 1999-06-08 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus
DK0644202T3 (da) * 1990-12-14 1997-09-15 Innogenetics Nv Syntetiske antigener til påvisning af antistoffer imod hepatitis C virus
KR930703613A (ko) * 1991-01-25 1993-11-30 챨스 엠. 브록 시료 희석물중 과산화물 디스뮤타제의 용도
ATE167522T1 (de) * 1991-01-31 1998-07-15 Abbott Lab Monoklonale antikörper gegen mögliche hcv- hüllregionen und methoden diese zu benutzen
EP0532746B1 (en) * 1991-03-26 1997-01-02 Dade International Inc. Assay for non-a non-b hepatitis
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
CA2065690A1 (en) * 1991-04-10 1992-10-11 Hiroaki Okamoto Non-a, non-b hepatitis related antigens, detection systems, polynucleotides and polypeptides
WO1992018532A1 (fr) * 1991-04-17 1992-10-29 Eisai Co., Ltd. Arn, adn et proteine antigenique virale du virus de l'hepatite non-a, non-b
EP0510952A1 (en) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus
PL169880B1 (pl) * 1991-05-08 1996-09-30 Chiron Corp Sposób wytwarzania produktu hybrydyzacji z kwasem nukleinowym wirusa zapalenia watroby C PL PL PL
ES2040615B1 (es) * 1991-05-27 1994-05-16 Nebrda Fernando Javi Bartolome Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis.
FR2677372B1 (fr) * 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
AT405053B (de) * 1991-06-10 1999-05-25 Lucky Ltd Hepatitis-c-diagnosemittel und -impfstoffe
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
ES2188583T3 (es) * 1991-06-24 2003-07-01 Chiron Corp Polipeptidos para el virus de la hepatitis c (hcv).
DE4209215A1 (de) 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
AU2513592A (en) * 1991-08-21 1993-03-16 Abbott Laboratories Hepatitis c assay utilizing recombinant antigens to ns1
DE69227776T2 (de) * 1991-08-21 1999-07-01 Abbott Laboratories, Abbott Park, Ill. Monoklonale antikörper gegen mutmassliche hepatitis c-virus ns5-proteine und ihre anwendungsmethoden
WO1993004089A1 (en) * 1991-08-21 1993-03-04 Abbott Laboratories Hepatitis c assay utilizing recombinant antigens from ns5 region
ES2111589T3 (es) * 1991-08-27 1998-03-16 Hoffmann La Roche Metodos y reactivos para la deteccion de la hepatitis c.
RU2212899C2 (ru) * 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
ZA927837B (en) * 1991-10-15 1994-03-11 Akzo Nv Monoclonal antibodiesto hepatitis C virus
JPH05130874A (ja) * 1991-11-07 1993-05-28 Sanwa Kagaku Kenkyusho Co Ltd ヒトＣ型肝炎ウイルスのｃＤＮＡ、そのクローン及びこれらの利用法
EP0573624A4 (en) * 1991-11-07 1997-09-17 Baxter Diagnostics Inc Epitope mapping ot the c33c region of hcv
EP0610436B9 (en) 1991-11-21 2003-03-26 Common Services Agency Hepatitis-c virus testing
JP3439209B2 (ja) * 1992-01-31 2003-08-25 アボツト・ラボラトリーズ Ｈｃｖ蛋白のための哺乳動物発現システム
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
US5866139A (en) * 1992-06-04 1999-02-02 Institut Pasteur Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications
US5980899A (en) * 1992-06-10 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells
UA39944C2 (uk) 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
US5859230A (en) * 1992-07-30 1999-01-12 Genelabs Technologies, Inc. Non-A/non-B/non-C/non-D/non-E hepatitis agents and molecular cloning thereof
DE4240980A1 (de) * 1992-08-07 1994-02-10 Boehringer Mannheim Gmbh HCV Peptidantigene und Verfahren zur Bestimmung von HCV
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6433159B1 (en) 1992-09-10 2002-08-13 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus associated diseases
WO1994005813A1 (en) 1992-09-10 1994-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Compositions and methods for treatment of hepatitis c virus-associated diseases
US6391542B1 (en) 1992-09-10 2002-05-21 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US6995146B2 (en) 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5922857A (en) * 1992-09-28 1999-07-13 Chiron Corporation Methods and compositions for controlling translation of HCV proteins
CN1059928C (zh) * 1992-09-29 2000-12-27 天津普生生物科技有限公司 利用大肠杆菌制备可用来检验c型肝炎之抗原蛋白的方法
JP2778886B2 (ja) * 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Ｃ型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット
EP0593291A3 (en) * 1992-10-16 1995-03-15 Evernew Biotech Inc Non-structural protein of the hepatitis C virus, as well as diagnostic procedure and test kit.
US6153378A (en) * 1992-10-16 2000-11-28 Bionova Corporation Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus
JPH06153959A (ja) * 1992-10-16 1994-06-03 Evernew Biotec Inc Ｃ型肝炎ウィルスの非構造タンパク質及びそれを用いての診断方法及びキット
FI952779L (fi) * 1992-12-07 1995-07-31 Akzo Nobel Nv HCV:n C33-alueen peptidejä, vasta-aineita niitä vastaan ja menetelmiä HCV:n toteamiseksi
KR950704353A (ko) * 1992-12-07 1995-11-20 에프.쥐.엠, 헤르만스 페.카.브론스 씨(c)형 간염 비루스(hcv) 비-구조-3 펩티드, 그에 대한 항체 및 에이취씨브이(hcv)의 검출 방법(hepatitis c virus(hcv) non-structurac-3 peptides, antibodies thereto and methods for the detection of hcv)
AU6769594A (en) * 1993-04-22 1994-11-08 Genelabs Technologies, Inc. Hepatitis c virus immunodiagnostic antigens and antibodies
EP0984068B1 (en) * 1993-04-27 2012-03-28 Innogenetics N.V. Sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
EP0698101B1 (en) 1993-05-05 2004-11-03 Common Services Agency Hepatitis-c virus type 4, 5 and 6
DK0698216T4 (da) 1993-05-10 2009-06-15 Novartis Vaccines & Diagnostic Fremgangsmåder til typebestemmelse af hepatitis-C-virus og anvendte reagenser heri
WO1994026306A1 (en) 1993-05-12 1994-11-24 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
WO1995011918A1 (en) * 1993-10-29 1995-05-04 Srl, Inc. Antigen peptide compound and immunoassay method
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
US6156495A (en) * 1994-02-14 2000-12-05 Abbott Laboratories Hepatitis GB virus recombinant proteins and uses thereof
US6051374A (en) * 1994-02-14 2000-04-18 Abbott Laboratories Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use
US6720166B2 (en) 1994-02-14 2004-04-13 Abbott Laboratories Non-a, non-b, non-c, non-c, non-d, non-e hepatitis reagents and methods for their use
US5843450A (en) * 1994-02-14 1998-12-01 Abbott Laboratories Hepatitis GB Virus synthetic peptides and uses thereof
US6558898B1 (en) 1994-02-14 2003-05-06 Abbott Laboratories Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use
US5981172A (en) * 1994-02-14 1999-11-09 Abbott Laboratories Non-A, non-B, non-C, non-D, non-E Hepatitis reagents and methods for their use
US6451578B1 (en) 1994-02-14 2002-09-17 Abbott Laboratories Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use
US5824507A (en) * 1994-05-20 1998-10-20 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
US5874563A (en) * 1994-05-20 1999-02-23 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
JP3217600B2 (ja) 1994-07-12 2001-10-09 株式会社先端生命科学研究所 非ａ非ｂ型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ
AU3241095A (en) * 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
DE69534296T2 (de) 1994-07-29 2006-04-27 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Sezernierter E1/E2-Komplex des Hepatitis C-Virus, des aus C-terminal verkürzten Polypeptiden E1 und E2 erhalten ist
DE4428705A1 (de) 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
US5955318A (en) * 1995-08-14 1999-09-21 Abbott Laboratories Reagents and methods useful for controlling the translation of hepatitis GBV proteins
US5807670A (en) * 1995-08-14 1998-09-15 Abbott Laboratories Detection of hepatitis GB virus genotypes
US5709997A (en) * 1995-08-14 1998-01-20 Abbott Laboratories Nucleic acid detection of hepatitis GB virus
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
GB9517926D0 (en) 1995-09-01 1995-11-01 Biocine Spa Binding protein
US5851758A (en) * 1995-10-25 1998-12-22 Childrens Research Institute Cytopathic replication of hepatitis C virus in a new cell line
US5837442A (en) 1995-11-29 1998-11-17 Roche Molecular Systems, Inc. Oligonucleotide primers for amplifying HCV nucleic acid
US5851759A (en) * 1996-04-19 1998-12-22 Chiron Corporation Heteroduplex tracking assay (HTA) for genotyping HCV
JP3715027B2 (ja) * 1996-05-07 2005-11-09 シスメックス株式会社 Ｃ型肝炎ウイルス感染症診断薬
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
DE69841015D1 (de) 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
US6010848A (en) * 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
US6153392A (en) * 1997-07-30 2000-11-28 Bionova Corporation Devices and methods comprising an HBcAg from hepatitis B virus
DE69841322D1 (de) 1997-10-06 2010-01-07 Novartis Vaccines & Diagnostic Hepatitis c rezeptorprotein cd81
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
CA2312484A1 (en) 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
EP1047784B2 (en) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Neissera meningitidis antigens
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261338A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
WO2000050078A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
EP1156781B1 (en) 1999-02-26 2005-06-08 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
JP2004508801A (ja) 1999-10-29 2004-03-25 カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ ナイセリア抗原性ペプチド
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
AR029903A1 (es) 2000-04-05 2003-07-23 Schering Corp Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento
CN101580536A (zh) 2000-04-19 2009-11-18 先灵公司 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
SI1354204T2 (sl) 2000-06-15 2010-09-30 Novartis Vaccines & Diagnostic Hcv antigen antitelo kombinacijska analiza
EP1829891B1 (en) * 2000-06-15 2012-12-26 Novartis Vaccines and Diagnostics, Inc. Immunoassays for Anti-HCV Antibodies
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
DK1385870T3 (da) 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
KR20030081297A (ko) 2000-07-21 2003-10-17 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
KR20030091946A (ko) 2000-12-12 2003-12-03 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 디아릴 펩티드
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
JP4608210B2 (ja) 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
US7196183B2 (en) 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
RU2331435C2 (ru) 2001-12-12 2008-08-20 Чирон Срл. Иммунизация против chlamydia trachomatis
US6894072B2 (en) 2002-01-23 2005-05-17 Schering Corporation Compounds as NS3-serine protease inhibitors of hepatitis C virus
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
ES2346717T3 (es) 2002-03-11 2010-10-19 Lab 21 Limited Metodo y composiciones para identificar y caracterizar la hepatitis c.
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
DK1521767T3 (da) 2002-05-24 2010-04-12 Medtronic Inc Fremgangsmåder og konstrukter til ekspression af clostripain med højt udbytte
ES2312806T3 (es) 2002-09-09 2009-03-01 Novartis Vaccines And Diagnostics, Inc. Ensayo de vhc.
US7115374B2 (en) 2002-10-16 2006-10-03 Gen-Probe Incorporated Compositions and methods for detecting West Nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
KR101173871B1 (ko) 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US7449447B2 (en) 2003-08-26 2008-11-11 Schering Corporation Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
CN1856503A (zh) 2003-09-22 2006-11-01 株式会社绿多肽 来源于c型肝炎病毒的肽
RU2006113880A (ru) 2003-09-26 2007-11-20 Шеринг Корпорейшн (US) Макроциклические ингибиторы сериновой протеиназы ns3 вируса гепатита с
WO2005037214A2 (en) * 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
MXPA06005683A (es) 2003-11-20 2006-12-14 Schering Corp Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c.
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7186747B2 (en) 2004-02-27 2007-03-06 Schering Corporation Compounds as inhibitors of hepatitis C virus NS3 serine protease
EP1737821B1 (en) 2004-02-27 2009-08-05 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
AU2005219859A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis C virus NS3 protease
CN1946691A (zh) 2004-02-27 2007-04-11 先灵公司 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的化合物
ES2328596T3 (es) 2004-05-20 2009-11-16 Schering Corporation Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c.
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
EP1802778B1 (en) 2004-08-27 2011-10-05 Novartis Vaccines and Diagnostics, Inc. Hcv multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof
ATE513844T1 (de) 2004-08-27 2011-07-15 Schering Corp Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
CA2618429A1 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
NZ563365A (en) 2005-06-02 2011-02-25 Schering Corp Combination of HCV protease inhibitors with a surfactant
AU2006252519B2 (en) 2005-06-02 2012-08-30 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
CA2623405C (en) 2005-09-20 2014-11-25 Immunivest Corporation Methods and composition to generate unique sequence dna probes labeling of dna probes and the use of these probes
WO2007135707A1 (ja) 2006-05-18 2007-11-29 Nichia Corporation 樹脂成形体及び表面実装型発光装置並びにそれらの製造方法
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US20090214593A1 (en) 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
EP2283112B1 (en) 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
CA2746258A1 (en) 2008-12-12 2010-06-17 Schering Corporation Deuterated compounds as hepatitis c virus (hcv) inhibitors
CA2754592A1 (en) 2009-03-09 2010-09-16 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
JP2012528195A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
AU2010341537A1 (en) 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
AU2011209051B2 (en) 2010-01-27 2015-01-15 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
WO2012171332A1 (zh) 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
JP6059220B2 (ja) 2011-07-06 2017-01-18 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
RU2014118727A (ru) 2011-10-11 2015-11-20 Новартис Аг Рекомбинантные самореплицирующиеся полицистронные молекулы рнк
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
CA2980718C (en) 2015-03-27 2021-06-01 Ortho-Clinical Diagnostics, Inc. Hcv ns4a/modified ns3 polypeptides and uses thereof
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464474A (en) * 1980-07-09 1984-08-07 Connaught Laboratories Limited Non-A, non-B hepatitis assay and vaccine
EP0071640B1 (en) * 1981-02-11 1986-06-04 Connaught Laboratories Incorporated Non-a, non-b hepatitis virus
US4702909A (en) * 1982-05-05 1987-10-27 Louisiana State University A & M Non-A, non-B hepatitis antigen, antigen compositions, vaccine and diagnostic reagent
US4673634A (en) * 1985-03-08 1987-06-16 The United States Of America As Represented By The Department Of Health And Human Services Purified antigen from non-A, non-B hepatitis causing factor
EP0261233A4 (en) * 1986-04-01 1988-08-29 Genelabs Inc IMMORTALIZED TISSUE CELLS WITH VIRAL SPECIFICITY.
JPS6391328A (ja) * 1986-10-07 1988-04-22 Mitsubishi Kasei Corp 非ａ非ｂ型肝炎抗原
NZ222465A (en) * 1986-11-07 1992-11-25 Pasteur Institut Nanb (non a, non b hepatitis viral) antigen
DE3744242A1 (de) * 1987-02-20 1989-07-06 Seelig Renate Virusantigen, verfahren zu seiner gewinnung und anwendung in diagnose und therapie (impfstoff)
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004506018A (ja) * 2000-08-17 2004-02-26 トリペップ　アクチ　ボラゲット リバビリンを含むワクチンおよびその使用方法

Also Published As

Publication number Publication date
JPH10108674A (ja) 1998-04-28
JP2007197456A (ja) 2007-08-09
NO892931D0 (no) 1989-07-17
CN1285514A (zh) 2001-02-28
JP2000023683A (ja) 2000-01-25
JPH02500880A (ja) 1990-03-29
CN1299973A (zh) 2001-06-20
CN1159584C (zh) 2004-07-28
GR900300069T1 (en) 1991-07-31
HU211905A9 (en) 1996-01-29
KR19980701583A (ko) 1998-05-15
LV10726A (lv) 1995-06-20
JP2662351B2 (ja) 1997-10-08
JP2809956B2 (ja) 1998-10-15
WO1989004669A1 (en) 1989-06-01
CN1249433A (zh) 2000-04-05
CN100397082C (zh) 2008-06-25
JP2008007508A (ja) 2008-01-17
JP2810022B2 (ja) 1998-10-15
IE883472L (en) 1989-05-18
JPH06128292A (ja) 1994-05-10
EP0318216B1 (en) 1993-12-15
FI893447A7 (fi) 1989-07-17
FI107620B (fi) 2001-09-14
EP0318216B2 (en) 2001-08-29
CN1049686C (zh) 2000-02-23
LV10726B (en) 1995-12-20
KR0138776B1 (ko) 1998-05-15
UA42668C2 (uk) 2001-11-15
DE318216T1 (de) 1990-06-13
HK38293A (en) 1993-04-30
DE3886363T3 (de) 2004-09-09
FI105652B (fi) 2000-09-29
HK1033773A1 (en) 2001-09-21
JP2532805B2 (ja) 1996-09-11
NO892931L (no) 1989-09-13
FI106564B (fi) 2001-02-28
BR8807310A (pt) 1990-03-13
FI981380L (fi) 1998-06-15
HUT53148A (en) 1990-09-28
NO304990B1 (no) 1999-03-15
CA1341629C (en) 2012-05-08
JPH06128290A (ja) 1994-05-10
KR890701126A (ko) 1989-12-19
JP3171793B2 (ja) 2001-06-04
NZ227011A (en) 1992-03-26
JP2662358B2 (ja) 1997-10-08
HU216017B (hu) 1999-04-28
KR100216013B1 (ko) 1999-08-16
ES2012739T3 (es) 1994-12-01
JP2006104207A (ja) 2006-04-20
JP2662350B2 (ja) 1997-10-08
CN1035679A (zh) 1989-09-20
DE3886363D1 (de) 1994-01-27
JPH10290696A (ja) 1998-11-04
HU9502949D0 (en) 1995-12-28
JPH06225797A (ja) 1994-08-16
ES2012739A4 (es) 1990-04-16
JP2006117681A (ja) 2006-05-11
FI981380A0 (fi) 1988-11-18
JPH06128293A (ja) 1994-05-10
CN1129796C (zh) 2003-12-03
JPH06128291A (ja) 1994-05-10
DE3886363T2 (de) 1994-05-19
CN1073719A (zh) 1993-06-30
JPH09184844A (ja) 1997-07-15
JPH10290697A (ja) 1998-11-04
FI20001390A7 (fi) 2000-06-12
EP0318216A1 (en) 1989-05-31
AU2796789A (en) 1989-06-14
ES2012739T5 (es) 2001-12-01
IE62868B1 (en) 1995-03-08
JP2810032B2 (ja) 1998-10-15
JPH09173079A (ja) 1997-07-08
HK1026023A1 (en) 2000-12-01
FI893447A0 (fi) 1989-07-17
HU220204B (hu) 2001-11-28
CN1074422C (zh) 2001-11-07

Similar Documents

Publication Publication Date Title
JP2662358B2 (ja) Ｎａｎｂｖの診断用薬
JP3514751B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）ポリペプチド
JP2809987B2 (ja) Ｎａｎｂｖの診断用薬
DK175975B1 (da) NANBV-diagnostika og -vacciner
DK176280B1 (da) NANBV-diagnostika og -vacciner
HRP940493A2 (en) Nanbv diagnostics and vaccines

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071115

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081115

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091115

Year of fee payment: 16

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091115

Year of fee payment: 16

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091115

Year of fee payment: 16

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091115

Year of fee payment: 16